Sana Biotechnology pursues a novel approach in engineered cell therapies via its ex vivo hypoimmune platform and in vivo fusogen delivery system, with lead candidates targeting type 1 diabetes and B cell-driven diseases. Despite encouraging early clinical signals around immune evasion without immunosuppression, the company’s operations continue at a net loss, burdened by substantial cash burn and legal uncertainties. Looking forward, milestones include IND filing and Phase 1 initiation for SC451, with potential regulatory and reimbursement risks tempering prospects. Capital allocation emphasizes funding R&D given ongoing losses, supported by a cash balance of approximately $72 million as of end-2025.